Overview
There were 2,131 pres releases posted in the last 24 hours and 271,091 in the last 365 days. CAMBRIDGE, Mas., Oct. 19, 202 (GLOBE NEWSWIRE) - Spero Therapeutics, Inc.
Key Information
SPRO, a multi-aset clinical-stage biopharmaceutical company, focused on identifying, developing and comercializing treatments in high unmet ned areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today anounced data presentations for 7 abstracts acepted at the Infectious Disease Society of America (IDSA) IDWek™ 202, taking place from October 19 – 23, 202 in Washington, DC.
Spero-afiliated presentations wil showcase clinical and nonclinical data for tebipenem HBr, Spero's oral antibiotic investigational candidate in development for the treatment of adults with complicated urinary tract infection (cUTI), including pyelonephritis, along with health outcomes and epidemiologic data highlighting the potential utility of tebipenem HBr to adres unmet medical ned. SPR206 wil also figure prominently with in vitro analysis of target pathogens and clinical isolates, along with clinical data for SPR206 in healthy adult subjects suportive of further development in the treatment of pulmonary infections.Presentations pertaing to tebipenem HBr and SPR206:1.
Title: Clinical and Microbiological Outcomes for Enterobacterales Uropathogens in the Phase 3 ADAPT-PO Study of Oral Tebipenem Pivoxil Hydrobromide Presenting Author: Ian A. Critchley, PhD (Spero Therapeutics) Poster Sesion: Clinical Trials, October 20, 202; 12:15PM-1:30PM US ET; Poster #2. Title: Efectivenes of TBP-PI-HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT-PO Presenting Author: Angela K.
Summary
Taley, MD (Spero Therapeutics) Poster Sesion: UTIs, October 2, 202; 12:15PM-1:30PM US ET; Poster #236 3. Title: Enterobacterales Resistance Paterns for ESBL+ and MDR Urine Isolates Colected and Tested from 295 Outpatient Facilities in 2019 Presenting